Recent News

• 03.31.2026 - Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
• 03.25.2026 - Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

Recent Filings

• 03.19.2026 - EFFECT Notice of Effectiveness
• 03.11.2026 - S-3 Registration statement under Securities Act of 1933
• 03.11.2026 - EX-99.1 EX-99.1
• 03.11.2026 - 8-K Current report
• 03.11.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.10.2026 - 144 Report of proposed sale of securities
• 03.10.2026 - 144 Report of proposed sale of securities
• 03.10.2026 - 144 Report of proposed sale of securities
• 02.20.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.17.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors